Research Report Screener Results

Chart, Financials, Historical Prices, Industry, Insider, Messages, News, Options, Profile, Reports, Research, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 25-May-2013
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 24)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
25-May-13 Stock Traders Daily Thomas H Kee Jr. Trading Report for (TEVA). A detailed report, including free correlated market analysis, and updates. 5 $57.50 View Abstract
24-May-13 Reuters Investment Profile N/A Teva Pharmaceutical Industries Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $138 View Abstract
24-May-13 New Constructs, LLC N/A TEVA: Due Diligence Review: Forensic Earnings and Valuation 13 $25 View Abstract
24-May-13 Ford Investor Services, Inc. N/A Industry Value Graph: BAYRY , BMY , LLY , SNY , TEVA -- DRUGS 3 $34.50 View Abstract
23-May-13 Plunkett Research, Ltd. Jack W Plunkett Teva Pharmaceutical Industries Ltd (TEVA) Profile and Financials, plus Nanotechnology Industry Trends Analysis, Operating Ratios and Financial Averages 32 $99 View Abstract
23-May-13 Plunkett Research, Ltd. Jack W Plunkett Teva Pharmaceutical Industries Ltd (TEVA) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratios and Financial Averages 52 $99 View Abstract
23-May-13 Plunkett Research, Ltd. Jack W Plunkett Teva Pharmaceutical Industries Ltd (TEVA) Profile and Financials, plus Biotechnology Industry Trends Analysis, Operating Ratios and Financial Averages 49 $99 View Abstract
23-May-13 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for TEVA 11 $126.50 View Abstract
23-May-13 Wright Reports N/A Wright Investors Service Comprehensive Report for Teva Pharmaceutical Industries Limited 42 $483 View Abstract
21-May-13 Stock Traders Daily Thomas H Kee Jr. The Investment Rate - a measure of investment demand. 43 $494.50 View Abstract
Next 14

Independent Reports (Showing 1 to 10 of 24)

Release
Date Contributor Author Title Pages Price More Info
25-May-13 Stock Traders Daily Thomas H Kee Jr. Trading Report for (TEVA). A detailed report, including free correlated market analysis, and updates. 5 $57.50 View Abstract
24-May-13 Reuters Investment Profile N/A Teva Pharmaceutical Industries Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $138 View Abstract
24-May-13 New Constructs, LLC N/A TEVA: Due Diligence Review: Forensic Earnings and Valuation 13 $25 View Abstract
24-May-13 Ford Investor Services, Inc. N/A Industry Value Graph: BAYRY , BMY , LLY , SNY , TEVA -- DRUGS 3 $34.50 View Abstract
23-May-13 Plunkett Research, Ltd. Jack W Plunkett Teva Pharmaceutical Industries Ltd (TEVA) Profile and Financials, plus Nanotechnology Industry Trends Analysis, Operating Ratios and Financial Averages 32 $99 View Abstract
23-May-13 Plunkett Research, Ltd. Jack W Plunkett Teva Pharmaceutical Industries Ltd (TEVA) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratios and Financial Averages 52 $99 View Abstract
23-May-13 Plunkett Research, Ltd. Jack W Plunkett Teva Pharmaceutical Industries Ltd (TEVA) Profile and Financials, plus Biotechnology Industry Trends Analysis, Operating Ratios and Financial Averages 49 $99 View Abstract
23-May-13 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for TEVA 11 $126.50 View Abstract
23-May-13 Wright Reports N/A Wright Investors Service Comprehensive Report for Teva Pharmaceutical Industries Limited 42 $483 View Abstract
21-May-13 Stock Traders Daily Thomas H Kee Jr. The Investment Rate - a measure of investment demand. 43 $494.50 View Abstract
Next 14

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.